ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Direct Indexing
    • Disruptive Technology
    • Energy Infrastructure
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Financial Literacy
    • Fixed Income
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Modern Alpha
    • Multifactor
    • Night Effect
    • Portfolio Strategies
    • Responsible Investing
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Biotech ETF Rallies on Alzheimer Treatment Report
News
Share

Biotech ETF Rallies on Alzheimer Treatment Report

Ian YoungOct 28, 2019
2019-10-28

Shares of Biogen Inc. rocketed higher on Tuesday, headed for their strongest performance in 20 years, after the biotechnology company surprised investors by stating that its Alzheimer’s treatment was prepared to start the regulatory approval process, as well as from third-quarter earnings that handily beat expectations.

The biotech company said its decision to move forward with the approval of aducanumab, an treatment for early Alzheimer’s diseases was determined after the drug met the primary endpoint of a Phase 3 Emerge study, and after consulting with the U.S. Food and Drug Administration.

This is a reversal from the company’s statement last March when it said it would discontinue the trials after lackluster results. Over $15 billion in market value was wiped after the company said it wouldn’t be moving forward.

The iShares NASDAQ Biotechnology ETF (IBB A-) rallied more than 3% at its high on Tuesday on the news, which represented its best daily gain since January 7, as Biogen powered the ETF higher.

Wall Street was also shocked by the Biogen’s announcement.

“Today’s announcement to submit for approval comes as unexpected,” Wedbush analyst Laura Chico wrote in a note to clients. Guggenheim’s Yatin Suneja said “this is an interesting development, and certainly unexpected.” And Alethia Young from Cantor Fitzgerald said she was “very shocked.”

Biogen’s rally aided other biotech names as well, including Vertex Pharmaceuticals, which gained 4%, as well as Gilead, Celgene, Regeneron, and Endo International, all of which climbed more than 1% on the news.

The news is particularly significant, as the drug would be the first of its kind in the Alzheimer’s market, which is worth billions of dollars. Still, given the drug trial’s history, the analysts remain somewhat skeptical.

“While the headline sounds positive (and very well could mean the company has an Alzheimer’s drug), the news today alone does not guarantee approval and questions remain,” Mizuho analyst Salim Syed wrote in a note to clients. He has a neutral rating on the stock, and $235 target.

Morgan Stanley’s Matthew Harrison agreed, saying that there are “a range of questions that will need to be addressed for investors to gain confidence in this strategy.”

Before the announcement, Biogen reported third-quarter earnings that topped Wall Street’s expectations as well, with earnings per share at $9.17 on revenue of $3.60 billion. Analysts had forecast earnings of $8.27 per share on revenue of $3.539 billion.

This article originally appeared on ETFTrends.com.


Content continues below advertisement

» Popular Pages

  • Tickers
  • Articles

Jun 01

Mega-Caps for Mega Returns? The USMC ETF

Jun 01

When Broad Commodities Tumble, Consider Carbon Allowances

Jun 01

Hartford Rolls Out Active Core Bond ETF Strategy

Jun 01

Advisors Can Use Multifactor ETF ROUS to Take Smarter Risks

Jun 01

Currency-Hedged ETF DXJ Nears $2 Billion

Jun 01

Exchange Registration Now Open to Advisors

Jun 01

In Market Uncertainty, Play the Long Game Using Nationwide ETFs

Jun 01

CNBC Interviews John Davi About ETF Flows & AI

Jun 01

The Tech Sector Thumbs Its Nose at Higher Rates

Jun 01

Three Keys to Active ETF Investing in 2023

QQQ

Invesco QQQ Trust

SPY

SPDR S&P 500 ETF Trust

JEPI

JPMorgan Equity Premium...

VTI

Vanguard Total Stock Market...

VOO

Vanguard S&P 500 ETF

VGT

Vanguard Information...

TLT

iShares 20+ Year Treasury...

BND

Vanguard Total Bond Market...

XLP

Consumer Staples Select...

BOTZ

Global X Robotics &...


Content continues below advertisement

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X